Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling

Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiya, Naoyuki, Murai, Moeka, Hosoda, Ayumi, Yonezawa, Honami, Omori, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/
https://www.ncbi.nlm.nih.gov/pubmed/31703435
http://dx.doi.org/10.3390/ph12040165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/
https://www.ncbi.nlm.nih.gov/pubmed/31703435
http://dx.doi.org/10.3390/ph12040165

Ejemplares similares